• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

单机构中胶质母细胞瘤荧光引导切除与白光切除的结果

Outcomes of Fluorescence-Guided vs White Light Resection of Glioblastoma in a Single Institution.

作者信息

Wong Li Siang, St George Jerome, Agyemang Kevin, Grivas Athanasios, Houston Deborah, Foo Sin Yee, Mullan Thomas

机构信息

General Medicine, Royal Alexandra Hospital, Paisley, GBR.

Neurosurgery, Queen Elizabeth University Hospital, Glasgow, GBR.

出版信息

Cureus. 2023 Jul 30;15(7):e42695. doi: 10.7759/cureus.42695. eCollection 2023 Jul.

DOI:10.7759/cureus.42695
PMID:37649945
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10465263/
Abstract

Background Glioblastoma (GBM) is the most common malignant primary brain tumour and confers a very poor prognosis. Maximal safe resection of tumour is the goal of neurosurgical intervention and may be more easily achieved through the use of surgical adjuncts such as fluorescence-guided surgery (FGS). 5-Aminolevulinic acid (5-ALA) accumulates in GBM tissue and fluoresce red, distinguishing tumour cells from the surrounding tissue and therefore making resection easier. 5-ALA-guided resection in GBM has been shown to increase resection rates and prolong progression-free survival without impacting post-operative morbidity. Radiotherapy and concomitant chemotherapy also improve survival in GBM. Other factors such as patient age and molecular status of the tumour also impact prognosis. Aims The aim of this study was to compare the outcomes of 5-ALA vs white light-guided resection for glioblastoma in the west of Scotland. Methods  This was a retrospective analysis of baseline characteristics (age, sex, tumour molecular markers, radiotherapy, chemotherapy, anatomical location of tumour and treatment group) and outcomes (mortality, survival, degree of resection and performance status) of 239 patients who underwent primary resection of glioblastoma over a four-year period (2017-2020). A variety of statistical methods were used to analyse the relationship between each variable and surgical technique; multivariate Cox regression and the Kaplan-Meier method were used in survival analysis. Results  5-ALA-guided resection substantially improved resection rates (74.0% vs 40.2%). Mortality at 15 months was 5.1% lower in the 5-ALA group (52.0% vs 57.1%, p = 0.53), and patients lived an average of 68 days longer compared to the white light group (444 days vs 376 days, p = 0.21). There were negligible differences between treatment groups in terms of post-operative performance status (PS) and post-operative complications. In our multivariate Cox regression model, six factors were statistically significant at a level of p ≤ 0.05: age, radiotherapy, chemotherapy, O(6)-methylguanine-DNA methyltransferase (MGMT) methylation, anatomical location and >90% resection. Receiving chemotherapy and radiotherapy, MGMT methylation and undergoing >90% resection conferred a survival benefit at 15 months. Older age and multi-focal disease were related to a worsened mortality rate. Undergoing radiotherapy and maximal resection were the two greatest predictors of improved survival, reducing mortality risk by 58% and 51%, respectively. Conclusion 5-ALA-guided resection improved resection rates without impacting post-operative morbidity. 5-ALA-guided resection was associated with improved survival and lower mortality rate, but this was not statistically significant. Receiving chemoradiotherapy, MGMT methylation and undergoing maximal resection conferred a survival benefit, whilst older age and multi-focal disease were associated with a poorer prognosis.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af76/10465263/c24d6eba9729/cureus-0015-00000042695-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af76/10465263/70f0971c9854/cureus-0015-00000042695-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af76/10465263/691d7178a0f3/cureus-0015-00000042695-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af76/10465263/c24d6eba9729/cureus-0015-00000042695-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af76/10465263/70f0971c9854/cureus-0015-00000042695-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af76/10465263/691d7178a0f3/cureus-0015-00000042695-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af76/10465263/c24d6eba9729/cureus-0015-00000042695-i03.jpg
摘要

背景

胶质母细胞瘤(GBM)是最常见的原发性恶性脑肿瘤,预后极差。肿瘤的最大安全切除是神经外科干预的目标,通过使用荧光引导手术(FGS)等手术辅助手段可能更容易实现。5-氨基酮戊酸(5-ALA)在GBM组织中蓄积并发出红色荧光,将肿瘤细胞与周围组织区分开来,从而使切除更容易。已证明5-ALA引导下的GBM切除术可提高切除率并延长无进展生存期,且不影响术后发病率。放疗和同步化疗也可改善GBM患者的生存期。其他因素,如患者年龄和肿瘤的分子状态,也会影响预后。目的:本研究旨在比较5-ALA引导与白光引导下切除苏格兰西部胶质母细胞瘤的疗效。方法:这是一项对239例在四年期间(2017 - 2020年)接受胶质母细胞瘤初次切除的患者的基线特征(年龄、性别、肿瘤分子标志物、放疗、化疗、肿瘤的解剖位置和治疗组)及疗效(死亡率、生存期、切除程度和功能状态)进行的回顾性分析。使用多种统计方法分析每个变量与手术技术之间的关系;生存分析采用多变量Cox回归和Kaplan-Meier方法。结果:5-ALA引导下的切除术显著提高了切除率(74.0%对40.2%)。5-ALA组15个月时的死亡率比白光组低5.1%(52.0%对57.1%,p = 0.53),且患者的平均生存期比白光组长68天(444天对376天,p = 0.21)。治疗组在术后功能状态(PS)和术后并发症方面差异可忽略不计。在我们的多变量Cox回归模型中,六个因素在p≤0.05水平上具有统计学意义:年龄、放疗、化疗、O(6)-甲基鸟嘌呤-DNA甲基转移酶(MGMT)甲基化、解剖位置和切除率>90%。接受化疗和放疗、MGMT甲基化以及切除率>90%在15个月时具有生存获益。年龄较大和多灶性疾病与死亡率恶化相关。接受放疗和最大程度切除是生存期改善的两个最大预测因素,分别将死亡风险降低58%和51%。结论:5-ALA引导下的切除术提高了切除率,且不影响术后发病率。5-ALA引导下的切除术与生存期改善和死亡率降低相关,但无统计学意义。接受放化疗、MGMT甲基化以及进行最大程度切除具有生存获益,而年龄较大和多灶性疾病与预后较差相关。

相似文献

1
Outcomes of Fluorescence-Guided vs White Light Resection of Glioblastoma in a Single Institution.单机构中胶质母细胞瘤荧光引导切除与白光切除的结果
Cureus. 2023 Jul 30;15(7):e42695. doi: 10.7759/cureus.42695. eCollection 2023 Jul.
2
Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.辅助治疗后不可切除胶质母细胞瘤中MGMT启动子状态的预后价值
Clin Neurol Neurosurg. 2015 May;132:1-8. doi: 10.1016/j.clineuro.2015.01.029. Epub 2015 Feb 7.
3
Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.替莫唑胺长期治疗是新诊断胶质母细胞瘤的一种可行选择:一家机构多达101个替莫唑胺疗程的经验。
Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.
4
Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit.局部烷化剂化疗在 5-ALA 引导下切除胶质母细胞瘤后立即应用并不能提供额外的益处。
J Neurooncol. 2018 Jan;136(2):273-280. doi: 10.1007/s11060-017-2649-8. Epub 2017 Nov 14.
5
Association of molecular marker O(6)Methylguanine DNA methyltransferase and concomitant chemoradiotherapy with survival in Southern Chinese glioblastoma patients.中国南方胶质母细胞瘤患者中分子标志物 O(6)-甲基鸟嘌呤-DNA 甲基转移酶与同期放化疗生存的相关性。
Hong Kong Med J. 2011 Jun;17(3):184-8.
6
A pilot study of glioblastoma multiforme in elderly patients: treatments, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status and survival.老年多形性胶质母细胞瘤的一项初步研究:治疗、O-6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)甲基化状态与生存情况
Clin Neurol Neurosurg. 2013 Aug;115(8):1375-8. doi: 10.1016/j.clineuro.2012.12.023. Epub 2013 Jan 18.
7
Use of 5-ALA fluorescence-guided surgery versus white-light conventional microsurgery for the resection of newly diagnosed glioblastomas (RESECT study): a French multicenter randomized phase III study.5-ALA 荧光引导手术与白光常规显微镜手术在新诊断的胶质母细胞瘤切除中的应用(RESECT 研究):一项法国多中心随机 III 期研究。
J Neurosurg. 2023 Oct 13;140(4):987-1000. doi: 10.3171/2023.7.JNS231170. Print 2024 Apr 1.
8
5-Aminolevulinic acid-guided resection improves the overall survival of patients with glioblastoma-a comparative cohort study of 343 patients.5-氨基酮戊酸引导下的切除术改善胶质母细胞瘤患者的总生存期——343例患者的比较队列研究
Neurooncol Adv. 2021 Mar 26;3(1):vdab047. doi: 10.1093/noajnl/vdab047. eCollection 2021 Jan-Dec.
9
O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.O(6)-甲基鸟嘌呤-DNA 甲基转移酶(MGMT)启动子甲基化和低 MGMT 编码蛋白表达作为初始手术后行放疗联合替莫唑胺辅助治疗的胶质母细胞瘤患者的预后标志物,治疗中使用了可生物降解的卡莫司汀植入物。
Cancer. 2012 Sep 15;118(18):4545-54. doi: 10.1002/cncr.27441. Epub 2012 Feb 22.
10
Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.组蛋白 H3 赖氨酸 4 甲基转移酶 MLL4 和组蛋白 H3 赖氨酸 27 去甲基酶 UTX 的表达增加,延长了具有甲基化 MGMT 启动子的胶质母细胞瘤患者的总生存期。
J Neurosurg. 2017 May;126(5):1461-1471. doi: 10.3171/2016.4.JNS1652. Epub 2016 Jul 1.

引用本文的文献

1
Comparative Analysis of 5-ALA and Fluorescent Techniques in High-Grade Glioma Treatment.5-氨基乙酰丙酸与荧光技术在高级别胶质瘤治疗中的对比分析
Biomedicines. 2025 May 10;13(5):1161. doi: 10.3390/biomedicines13051161.
2
Noninvasive Ultra Low Intensity Light Photodynamic Treatment of Glioblastoma with Drug Augmentation: LoGlo PDT Regimen.药物增强的胶质母细胞瘤非侵入性超低强度光动力治疗:低强度光动力疗法方案
Brain Sci. 2024 Nov 21;14(12):1164. doi: 10.3390/brainsci14121164.
3
Fluorescence in neurosurgery: its therapeutic and diagnostic significance - a comprehensive review.

本文引用的文献

1
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.2021 年世卫组织中枢神经系统肿瘤分类:概述。
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
2
Awake craniotomy for resection of supratentorial glioblastoma: a systematic review and meta-analysis.清醒开颅手术切除幕上胶质母细胞瘤:一项系统评价和荟萃分析。
Neurooncol Adv. 2020 Sep 18;2(1):vdaa111. doi: 10.1093/noajnl/vdaa111. eCollection 2020 Jan-Dec.
3
Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis.
神经外科中的荧光:其治疗与诊断意义——一篇综述
Ann Med Surg (Lond). 2024 May 23;86(7):4255-4261. doi: 10.1097/MS9.0000000000002218. eCollection 2024 Jul.
胶质母细胞瘤切除范围与生存的相关性:一项系统评价和荟萃分析。
JAMA Oncol. 2016 Nov 1;2(11):1460-1469. doi: 10.1001/jamaoncol.2016.1373.
4
Current trends in the management of glioblastoma in a French University Hospital and associated direct costs.法国一家大学医院胶质母细胞瘤的管理现状及相关直接成本
J Clin Pharm Ther. 2016 Feb;41(1):47-53. doi: 10.1111/jcpt.12346. Epub 2016 Jan 8.
5
JAMA Oncology Patient Page. Performance Status in Patients With Cancer.《美国医学会杂志·肿瘤学》患者专页。癌症患者的体能状态。
JAMA Oncol. 2015 Oct;1(7):998. doi: 10.1001/jamaoncol.2015.3113.
6
What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas?使用5-氨基乙酰丙酸进行恶性胶质瘤荧光引导手术的外科手术益处是什么?
Neurosurgery. 2015 Nov;77(5):663-73. doi: 10.1227/NEU.0000000000000929.
7
Glioblastoma in England: 2007-2011.2007 - 2011年英国的胶质母细胞瘤。
Eur J Cancer. 2015 Mar;51(4):533-542. doi: 10.1016/j.ejca.2014.12.014. Epub 2015 Feb 3.
8
Risk factors for developing oral 5-aminolevulinic acid-induced side effects in patients undergoing fluorescence guided resection.荧光引导下切除术中患者发生 5-氨基酮戊酸诱导的口腔副作用的风险因素。
Photodiagnosis Photodyn Ther. 2013 Dec;10(4):362-7. doi: 10.1016/j.pdpdt.2013.03.007. Epub 2013 Apr 29.
9
Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic Acid-guided surgery.替莫唑胺胶囊联合放疗同步与序贯治疗脑胶质瘤的临床效果观察
Neurosurgery. 2013 Jun;72(6):915-20; discussion 920-1. doi: 10.1227/NEU.0b013e31828c3974.
10
Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival.脑胶质瘤患者的切除术范围:限制因素、可切除性感知及其对生存的影响。
J Neurosurg. 2012 Nov;117(5):851-9. doi: 10.3171/2012.8.JNS12234. Epub 2012 Sep 14.